Q-omics provides the consensus-scored CHURC1-FNTB profile across patient tissues and cancer cell-line models. CHURC1-FNTB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHURC1-FNTB is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CHURC1-FNTB RNA expression shows 15,720 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where CHURC1-FNTB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHURC1-FNTB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHURC1-FNTB survival associations across molecular data types. CHURC1-FNTB RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHURC1-FNTB RNA expression–survival associations across cancer types. High CHURC1-FNTB expression shows unfavorable associations in HNSC and READ, but favorable associations in KIRC, LGG, SKCM and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHURC1-FNTB RNA expression.
This table summarizes CHURC1-FNTB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CHURC1-FNTB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHURC1-FNTB shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, COAD, LUAD and KIRP. The HNSC box plot shows higher CHURC1-FNTB RNA expression in tumor versus normal tissue (log2 FC = +0.083, t-test p < 0.001).
This table shows molecular features associated with CHURC1-FNTB in patient tissues and cancer cell lines. In patient samples, CHURC1-FNTB shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHURC1-FNTB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
